Molecules in focus - The thrombopoietic factor, Mp1-ligand
- Author(s)
- Rasko, JEJ; Begley, CG;
- Details
- Publication Year 1998-06,Volume 30,Issue #6,Page 657-660
- Journal Title
- INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Publication Type
- Journal Article
- Abstract
- Mpl-ligand (thrombopoietin [TPO] or Megakaryocyte growth and development factor [MGDF]). was identified following the discovery of the oncogene, mpl. This oncogene encodes a truncated receptor belonging to the hemopoietin-receptor superfamily. Mpl-ligand consists of two domains; a carbohydrate-rich domain and an amino-terminal domain which displays homology to erythropoietin and is fully active. Mpl-ligand mRNA is predominantly expressed in liver and kidney and plasma levels are regulated by receptors expressed on megakaryocytes and platelets. Mpl-ligand is the most active single agent capable of promoting proliferation and maturation of cells within the megakaryocyte lineage. In addition to this 'lineage-specific' action, Mpl-ligand also acts on progenitor/stem cells of multiple hemopoietic lineages. Pre-clinical and early clinical studies have demonstrated the ability of Mpl-ligand to increase platelet counts and hasten platelet recovery after chemotherapy, This offers considerable promise for its use in clinical oncology. (C) 1998 Elsevier Science Ltd. All rights reserved.
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- MPL-DEFICIENT MICE; C-MPL; MEGAKARYOCYTE GROWTH; PLATELET PRODUCTION; PROGENITOR CELLS; IN-VIVO; LIGAND; THROMBOCYTOPENIA; PURIFICATION; STIMULATION
- Publisher's Version
- https://doi.org/10.1016/S1357-2725(97)00148-9
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 1998-06-01 12:00:00